Pterygium Removal Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

A pterygium (plural: pterygia) is a benign, wedge-shaped growth of fibrovascular conjunctival tissue that originates from the bulbar conjunctiva and extends across the limbus (corneoscleral junction) onto the corneal surface. The word derives from the Greek pterygion, meaning 'little wing', reflecting its characteristic triangular shape. Pterygia most commonly arise from the nasal side of the eye and grow toward the visual axis.

The condition is strongly associated with prolonged exposure to ultraviolet radiation, dry and dusty environments, and wind — earning the colloquial name surfer's eye. It is prevalent in equatorial and tropical regions and among outdoor workers. Smaller pterygia may be managed conservatively with lubricating eye drops and UV-protection sunglasses, but when the growth threatens the visual axis, causes significant astigmatism, produces persistent irritation, or advances despite conservative care, surgical excision is indicated.

Pterygium removal is a straightforward outpatient ophthalmic procedure performed under topical anaesthesia. The critical determinant of long-term success is not the excision itself but the technique used to close the resulting conjunctival defect — specifically, the use of a conjunctival autograft sourced from the patient's own superior bulbar conjunctiva, which has become the gold-standard technique to minimise recurrence.

Pterygium removal addresses the pterygium itself and its secondary consequences:

• Primary pterygium: A first-occurrence pterygium that has grown to involve the corneal surface, causing cosmetic concern, irritation, or visual disturbance.
• Advanced or progressive pterygium: Pterygia that have grown to within 2–3 mm of the corneal apex, threatening the central visual axis and risking visual impairment if untreated.
• Pterygium-induced astigmatism: Fibrovascular tissue pulling on the cornea distorts its curvature, inducing irregular astigmatism that degrades visual acuity and cannot be adequately corrected with spectacles or contact lenses.
• Symptomatic pterygium: Persistent redness, foreign body sensation, tearing, burning, or photophobia unresponsive to lubricating eye drops and non-surgical management.
• Recurrent pterygium: Re-growth of a pterygium previously removed with bare-sclera technique, now requiring more definitive excision with autograft or amniotic membrane transplantation.
• Pterygium prior to refractive surgery: Removal is required before LASIK or PRK to eliminate irregular astigmatism and ensure corneal topography stability.

Not all pterygia require surgery. The decision to operate is based on objective criteria and symptom burden:

• Encroachment toward visual axis: When the pterygium has grown within 3 mm of the central cornea (pupillary margin), surgery is usually recommended to prevent visual loss from further growth.
• Documented progression: Serial clinical photographs or corneal topography showing measurable growth over 6–12 months, even if the lesion has not yet reached the visual axis.
• Significant induced astigmatism: Pterygium-induced astigmatism of more than 1–2 dioptres affecting best-corrected visual acuity.
• Refractive surgery candidacy: Patients seeking LASIK or PRK must have pterygium removed first and corneal topography stabilised for at least 3 months before refractive measurements are taken.
• Cosmetic concern: When the patient has a strong cosmetic concern and surgical risk is acceptable, excision may be offered for smaller lesions.
• Contraindications: Active ocular infection, uncontrolled dry eye, severe blepharitis, or systemic coagulation disorders must be addressed before surgery. Patients on anticoagulants should liaise with their prescribing physician.

Multiple surgical techniques have been described for pterygium excision. The choice significantly impacts recurrence risk:

1. Conjunctival Autograft (CAG) — Gold Standard

Following excision of the pterygium and its underlying Tenon's capsule, a free graft of bulbar conjunctiva is harvested from the superior limbal region of the same eye (where the pterygium has not grown) and transplanted to cover the bare sclera defect. The graft is secured with absorbable sutures (10-0 Vicryl) or, increasingly, biological tissue adhesive (fibrin glue), which shortens operative time and reduces postoperative discomfort. Recurrence rates with CAG are consistently below 5% in published series — the lowest of any technique.

2. Amniotic Membrane Transplantation (AMT)

Cryopreserved or fresh amniotic membrane is used to cover the bare sclera instead of conjunctival autograft. AMT is preferred for large pterygia, recurrent pterygia, or when sufficient healthy conjunctiva is unavailable. Recurrence rates are somewhat higher than with CAG (8–15%) but superior to bare-sclera excision.

3. Bare-Sclera Excision (BSE)

The original technique, in which the pterygium is excised and the sclera is left uncovered to re-epithelialise spontaneously. Recurrence rates are unacceptably high (30–80%) and this technique is no longer recommended as standalone therapy by contemporary guidelines.

Adjunctive Mitomycin C (MMC): An anti-metabolite agent applied intraoperatively (or postoperatively via eye drops in some protocols) to inhibit fibroblast proliferation and reduce recurrence risk, particularly in high-risk or recurrent pterygia. Requires careful dosing to avoid scleral thinning or melting.

• Preservation of vision: Removing a pterygium that is approaching the visual axis prevents the progressive, potentially permanent visual loss associated with corneal invasion and deep stromal scarring.
• Reduction of induced astigmatism: Surgery eliminates the mechanical corneal distortion caused by the fibrovascular tissue, often resulting in significant improvement in uncorrected and best-corrected visual acuity.
• Relief of symptoms: Persistent redness, irritation, foreign body sensation, and tearing typically resolve within weeks of surgery, substantially improving daily comfort and quality of life.
• Cosmetic improvement: Removal of the visible red-white wing-shaped growth restores a clear, white ocular appearance, which many patients find psychologically significant.
• Outpatient procedure: Surgery takes 20–45 minutes under topical anaesthesia and requires no hospitalisation. Most patients drive themselves home the same day.
• Rapid return to work: Most patients with sedentary occupations can return to work within 3–7 days. Outdoor workers should plan for 2 weeks of UV protection and modified duties.
• Low recurrence with modern technique: Conjunctival autograft reduces recurrence to less than 5%, providing a durable, single-operation solution for the vast majority of patients.

Pterygium removal is generally very safe, but all surgical procedures carry potential complications:

• Recurrence: The most clinically significant concern. With bare-sclera excision, recurrence affects up to 80% of patients. Conjunctival autograft with or without mitomycin C reduces this to below 5%. Recurrent pterygia are often more aggressive and technically challenging to remove.
• Conjunctival graft complications: The autograft may partially dehisce, retract, or fail to vascularise. Meticulous suturing or use of fibrin glue minimises this risk.
• Corneal scarring: Residual corneal haze or subepithelial opacification may persist, particularly in long-standing or advanced pterygia where the lesion has invaded deep stromal layers.
• Dry eye exacerbation: Surgery disrupts the limbal and conjunctival anatomy, potentially worsening pre-existing dry eye. Lubricating drops should be continued for several months postoperatively.
• Mitomycin C complications: Over-application of MMC can cause scleral thinning (scleral melt), avascular sclera, or secondary glaucoma. Strict dosing protocols mitigate this risk.
• Infection: Postoperative conjunctivitis or keratitis is uncommon but requires prompt antibiotic treatment.
• Diplopia: Rarely, injury to or scarring around an extraocular muscle (particularly the medial rectus) during excision can cause double vision.
• Subconjunctival haemorrhage: Common and cosmetically alarming but self-resolving within 1–2 weeks.

Immediate post-operative period (day 0–3): The eye is typically patched for a few hours after surgery. Patients are prescribed antibiotic/steroid combination eye drops (e.g., tobramycin-dexamethasone) 4 times daily and lubricating artificial tears frequently. The eye may feel gritty, red, and photosensitive — this is normal and peaks in the first 3–5 days.

First 2 weeks: Avoid rubbing the eye at all costs. Swimming, contact lens wear, eye make-up, and dusty or smoky environments should be avoided for at least 2–4 weeks. UV-protective sunglasses should be worn outdoors at all times — this is critical both for comfort and for recurrence prevention.

Steroid taper: Topical steroids are typically continued for 4–8 weeks and tapered gradually to minimise inflammatory reactivation and reduce recurrence risk. Patients should not abruptly stop steroid drops without ophthalmologist guidance.

Follow-up visits:

• Day 1 or 2: Wound check, graft assessment
• Week 1–2: Suture removal (if absorbable sutures not used), inflammation assessment
• Month 1 and 3: Recurrence surveillance, refraction if visually significant pterygium was present
• Annually: Long-term recurrence monitoring and UV counselling

Long-term sun protection remains essential. Patients should wear UV-blocking wraparound sunglasses and a wide-brimmed hat when outdoors — ongoing UV exposure is the strongest driver of recurrence.

Pterygium removal is among the more affordable ophthalmic surgical procedures, though costs vary considerably by country, technique, and setting:

• Technique selected: Conjunctival autograft with fibrin glue is more expensive than bare-sclera excision due to the cost of fibrin glue (approximately USD 100–300 per use) and longer operative time. However, the superior recurrence outcomes make it cost-effective overall.
• Country and facility: Costs range from USD 300–700 per eye in India and Thailand to USD 2,000–5,000 in the United States or Australia. Private ophthalmology clinics in the UK charge GBP 1,500–3,000.
• Anaesthesia: Topical drops alone cost less than intravenous sedation or general anaesthesia, which may be preferred in anxious patients or complex cases.
• Adjuncts: Intraoperative mitomycin C and amniotic membrane transplantation (for recurrent pterygia) add to procedural cost.
• Postoperative medications: Antibiotic-steroid drops and lubricants used for 4–8 weeks represent an additional ongoing cost of approximately USD 50–200.
• Insurance: Surgery for medically indicated pterygium (visual threat, significant astigmatism) is typically covered by health insurance. Purely cosmetic excision of small pterygia may not be reimbursed.

• Conservative management: For small, non-progressive pterygia causing mild symptoms, lubricating preservative-free artificial tears, UV-blocking sunglasses, and avoidance of wind and dust can control symptoms indefinitely. Surgery is deferred unless the lesion progresses.
• Topical anti-inflammatory drops: Cyclosporine 0.05% (Restasis) or lifitegrast eye drops address the inflammatory component of pterygium-related dry eye and may slow progression in early lesions.
• Topical corticosteroids (short-term): Brief courses of mild topical steroids (e.g., fluorometholone 0.1%) reduce inflammation and conjunctival injection but do not eliminate the pterygium and carry risks of intraocular pressure elevation with prolonged use.
• Conjunctival injection of anti-VEGF agents: Subconjunctival bevacizumab (Avastin) injections have shown some efficacy in reducing vascularity and arresting growth of early pterygia in small studies. This remains an off-label, investigational approach not yet part of standard clinical care.
• Phototherapy (radiotherapy): Beta irradiation has historically been used as an adjunct after surgical excision to reduce recurrence, now largely replaced by mitomycin C due to the risk of late scleral necrosis with radiation.